糖尿病患者的胎儿胰腺干细胞移植
Fetal Pancreatic Stem-Cell Transplant in Patients With Diabetes Mellitus.
作者信息
Tuganbekova Saltanat, Ulyanova Olga, Taubaldieva Zhannat, Saparbayev Samat, Popova Nadezhda, Kozina Larissa
机构信息
From the Scientific Department of Internal Medicine, National Scientific Medical Research Center, Astana, Kazakhstan.
出版信息
Exp Clin Transplant. 2015 Nov;13 Suppl 3:160-2. doi: 10.6002/ect.tdtd2015.P89.
OBJECTIVES
To determine the efficacy of fetal stem cell transplant for treating patients with diabetes mellitus types 1 and 2.
MATERIALS AND METHODS
Five patients with diabetes mellitus type 1 and 5 patients with diabetes mellitus type 2 (aged 18-56 years) received a fetal pancreatic stem-cell transplant (cells were 16-18 wk gestation) performed by intravenous infusion at 50 mL/hour. The quantity of fetal stem cells infused was ≥ 5-8*106. We analyzed the patients' C-peptide and glycated hemoglobin levels both before and 3 months after fetal stem cell transplant.
RESULTS
In patients with diabetes mellitus type 1, fetal stem-cell transplant led to a significant increase in C-peptide levels, from 0.09 ± 0.01 ng/mL to 0.20 ± 0.07 ng/mL, after 3 months (P < .008).
CONCLUSIONS
Treatment with fetal pancreatic stem cells may be beneficial for treating patients with type 1 or type 2 diabetes.
目的
确定胎儿干细胞移植治疗1型和2型糖尿病患者的疗效。
材料与方法
5例1型糖尿病患者和5例2型糖尿病患者（年龄18 - 56岁）接受了胎儿胰腺干细胞移植（细胞取自妊娠16 - 18周的胎儿），通过静脉输注，速度为每小时50毫升。输注的胎儿干细胞数量≥5 - 8×10⁶。我们分析了患者在胎儿干细胞移植前及移植后3个月时的C肽和糖化血红蛋白水平。
结果
在1型糖尿病患者中，胎儿干细胞移植3个月后，C肽水平显著升高，从0.09±0.01纳克/毫升升至0.20±0.07纳克/毫升（P < 0.008）。
结论
胎儿胰腺干细胞治疗可能对治疗1型或2型糖尿病患者有益。
Zotero 插件